Hepatosplenomegaly, characterized by a simultaneous enlargement of the liver and the spleen, was significantly less pronounced in mice preventively, but not therapeutically, treated with CTLA-4-Ig compared to controls (Figure 2(a)). Here, CTLA4 is linked to Hepatosplenomegaly.